Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24297725 | 0.85 | MAPK14 (0.44) | ALDH1A1RAB9AMETLMNAABL1 | |
| SCHEMBL29077942 | 0.85 | MAPK14 (0.44) | ALDH1A1RAB9AMETLMNAABL1 | |
| SCHEMBL27211275 | 0.83 | ALDH1A1 (0.38) | ALDH1A1RAB9ASMN1; SMN2METLMNA | |
| SCHEMBL27211279 | 0.83 | ALDH1A1 (0.38) | ALDH1A1RAB9ASMN1; SMN2METLMNA | |
| SCHEMBL24298066 | 0.80 | FFAR2 (0.45) | ALDH1A1RAB9ASMN1; SMN2LMNAABL1 | |
| SCHEMBL27211133 | 0.79 | IDO1 (0.41) | ALDH1A1RAB9ASMN1; SMN2METLMNA | |
| SCHEMBL27211481 | 0.78 | FFAR2 (0.39) | ALDH1A1RAB9AMETLMNAFFAR2 | |
| SCHEMBL29564053 | 0.76 | FFAR2 (0.47) | ALDH1A1RAB9ALMNAFFAR2 | |
| SCHEMBL27210967 | 0.76 | ALDH1A1 (0.40) | ALDH1A1RAB9ASMN1; SMN2METLMNA | |
| SCHEMBL29457094 | 0.76 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | SLC6A4 4318/4885SLC6A2 2793/4885SLC6A3 3718/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | SLC6A4 4318/4885SLC6A2 2793/4885SLC6A3 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.